SNY stock sentiment todaySanofi SA
Sentiment verdict
Gossip first, financials second — NEUTRAL at 75% confidence.
Last updated · cached analysis, refreshes periodically
SNY
Sanofi SASanofi is a cash-flow powerhouse in transition, balancing the massive success of Dupixent against a thinning early-stage pipeline and recent restructuring costs.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for SNY. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the planned spin-off of its consumer healthcare unit (Opella) to focus on innovative medicines, similar to GSK and J&J moves. Investors are cautious about the 'Play to Win' strategy which sacrificed short-term margins for R&D spending.
- ·Consumer healthcare spin-off (Opella) valuation
- ·Dominance of Dupixent in immunology
- ·Pipeline replenishment concerns
- ·Recent cost-cutting initiatives
Financial
Solid balance sheet with strong free cash flow, though earnings per share have been pressured by increased R&D investment and tax rate changes. Valuation remains attractive compared to historical norms.
- ·Forward P/E ratio: ~11.5x
- ·Dividend Yield: ~3.8%
- ·Operating Margin: ~27-30%
- ·Net Debt/EBITDA: ~1.2x
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders bought a net $5.1M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Over-reliance on Dupixent for revenue growth
- ·R&D pipeline failure in late-stage trials
- ·Currency fluctuations (Euro vs USD)
- ·Drug pricing legislation in the US (IRA)
Peer temperature
How direct competitors stack up against SNY right now.
- HOTREGNRegeneron Pharmaceuticals
HOTTER — higher growth profile and larger share of Dupixent profits without the legacy pharma overhead.
See full analysis → - NEUTRALGSKGSK plc
SIMILAR — both completed consumer splits, but GSK has stronger recent momentum in vaccines (Arexvy).
See full analysis → - HOTNVSNovartis AG
HOTTER — superior margins and a more diversified portfolio of high-growth blockbuster drugs following its Sandoz spin-off.
See full analysis →
- SNY+15.3%
- REGN+32.3%
- GSK+5.5%
- NVS+14.6%
Analyst price target
Consensus average of 3 analysts · median 57.00
Source: StockAnalysis.com · updated 2026-08-31
AI-generated analysis for informational purposes only. Not financial advice.